Inventor · disambiguated record
Theodore Kamenecka
Also filed as: KAMENECKA THEODORE · KAMENECKA THEODORE M · KAMENECKA THEODORE MARK
26 granted patents·15 pending applications·174 citations·filing 2000–2024
95Inventor score
Files withKAMENECKA THEODORE MARK6MERCK & CO INC6SCRIPPS RESEARCH INST6ASTRAZENECA AB4EOLAS THERAPEUTICS INC4
Top patents by PatentIndex Score
41 records- 0194US6403584B1Substituted nipecotyl derivatives as inhibitors of cell adhesionMERCK & CO INC·Filed 2001·Granted Jun 11, 2002·52 cites·26 claims
- 0292US11434236B2Halo-substituted piperidines as orexin receptor modulatorsASTRAZENECA AB·Filed 2020·Granted Sep 6, 2022·2 cites·32 claims
- 0388US6353099B1Substituted ureas as cell adhesion inhibitorsMERCK & CO INC·Filed 2000·Granted Mar 5, 2002·25 cites·7 claims
- 0485US10221170B2Difluoropyrrolidines as orexin receptor modulatorsEOLAS THERAPEUTICS INC·Filed 2015·Granted Mar 5, 2019·7 cites·28 claims
- 0585US10016394B2PPARG modulators for treatment of osteoporosisSCRIPPS RESEARCH INST·Filed 2015·Granted Jul 10, 2018·3 cites·16 claims
- 0685US9440982B2Substituted prolines/piperidines as orexin receptor antagonistsEOLAS THERAPEUTICS INC·Filed 2014·Granted Sep 13, 2016·5 cites·26 claims
- 0785US8530480B2Substituted pyrimidinyl-amines as protein kinase inhibitorsKAMENECKA THEODORE·Filed 2008·Granted Sep 10, 2013·24 cites·15 claims
- 0884US10894789B2Halo-substituted piperidines as orexin receptor modulatorsASTRAZENECA AB·Filed 2017·Granted Jan 19, 2021·2 cites·30 claims
- 0983US9896452B2Substituted prolines/piperidines as orexin receptor antagonistsEOLAS THERAPEUTICS INC·Filed 2016·Granted Feb 20, 2018·5 cites·23 claims
- 1083US9586928B2Modulators of the nuclear hormone receptor RORKAMENECKA THEODORE MARK·Filed 2012·Granted Mar 7, 2017·5 cites·1 claims
- 1183US9499517B2Substituted prolines / piperidines as orexin receptor antagonistsEOLAS THERAPEUTICS INC·Filed 2014·Granted Nov 22, 2016·7 cites·12 claims
- 1282US2024400550A1Halo-substituted piperidines as orexin receptor modulatorsASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 1380US12084437B2Halo-substituted piperidines as orexin receptor modulatorsASTRAZENECA AB·Filed 2022·Granted Sep 10, 2024·0 cites·4 claims
- 1479US6943180B2Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitorsMERCK & CO INC·Filed 2002·Granted Sep 13, 2005·14 cites·28 claims
- 1579US6734311B2Substituted amidine derivatives as inhibitors of cell adhesionMERCK & CO INC·Filed 2001·Granted May 11, 2004·10 cites·2 claims
- 1677US9309227B2N-biphenylmethylbenzimidazole modulators of PPARGSCRIPPS RESEARCH INST·Filed 2012·Granted Apr 12, 2016·2 cites·11 claims
- 1776US11649234B2Nonmuscle myosin II inhibitors for substance use relapseSCRIPPS RESEARCH INST·Filed 2019·Granted May 16, 2023·1 cites·19 claims
- 1875US2025163056A1Nonmuscle myosin ii inhibitorsTHE UNIV OF FLORIDA RESEARCH FOUNDATION INC·Filed 2024·Application pending·0 cites
- 1974US7960417B2Benzazole potentiators of metabotropic glutamate receptorsMERCK SHARP & DOHME·Filed 2006·Granted Jun 14, 2011·2 cites·15 claims
- 2074US7700591B2Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptorsMERCK & CO INC·Filed 2005·Granted Apr 20, 2010·2 cites·18 claims
- 2173US12338240B2Nonmuscle myosin ii inhibitorsTHE UNIV OF FLORIDA RESEARCH FOUNDATION INC·Filed 2023·Granted Jun 24, 2025·0 cites·5 claims
- 2273US8957093B2N-biphenylmethylindole modulators of PPARGKAMENECKA THEODORE MARK·Filed 2012·Granted Feb 17, 2015·4 cites·5 claims
- 2367US9051265B2N-benzylindole modulators of PPARGKAMENECKA THEODORE MARK·Filed 2012·Granted Jun 9, 2015·2 cites·15 claims
- 2467US2024009169A9PPARG Modulators for the Treatment of OsteoporosisUNIV FLORIDA·Filed 2021·Application pending·0 cites
- 2560US10744117B2PPARG modulators for the treatment of osteoporosisSCRIPPS RESEARCH INST·Filed 2018·Granted Aug 18, 2020·0 cites·14 claims
- 2655US2023263808A1Therapeutic uses of glucocorticoids with anabolic effects in skeletal muscleUNIV FLORIDA·Filed 2021·Application pending·0 cites
- 2755US2023339886A1Rev-erb agonists for the treatment of th17-mediated inflammatory disordersUNIV FLORIDA·Filed 2021·Application pending·0 cites
- 2851US11365177B2Chemical uncouplers of respiration and methods of use thereofDANA FARBER CANCER INST INC·Filed 2018·Granted Jun 21, 2022·0 cites·19 claims
- 2951US2007060618A1Alkyne derivatives as tracers for metabotropic glutamate receptor bindingMERCK & CO INC·Filed 2003·Application pending·0 cites
- 3050US9018205B2Substituted pyrimidinyl-amines as protein kinase inhibitorsKAMENECKA THEODORE MARK·Filed 2013·Granted Apr 28, 2015·0 cites·10 claims
- 3149US11247970B2Selective inhibition of gluconeogenic activityDANA FARBER CANCER INST INC·Filed 2018·Granted Feb 15, 2022·0 cites·13 claims
- 3247US2014288090A1N-arylylmethylindazole modulators of ppargKAMENECKA THEODORE MARK·Filed 2012·Application pending·0 cites
- 3347US2007027321A1Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5KAMENECKA THEODORE M·Filed 2004·Application pending·0 cites
- 3444US2005085523A1Imidazolyl and pyrazolyl ethyne compoundsFiled 2004·Application pending·0 cites
- 3542US2015232429A1Substituted pyrimidinyl-amines as protein kinase inhibitorsSCRIPPS RESEARCH INST·Filed 2015·Application pending·0 cites
- 3642US2014249196A1N-benzylbenzimidazole modulators of ppargKAMENECKA THEODORE MARK·Filed 2012·Application pending·0 cites
- 3741US2007149547A1Bipyridyl amides as modulators of metabotropic glutamate receptor-5BONNEFOUS CELINE·Filed 2005·Application pending·0 cites
- 3841US2008293684A1Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate ReceptorsPINKERTON ANTHONY B·Filed 2005·Application pending·0 cites
- 3939US2008312286A1Indanone Potentiators of Metabotropic Glutamate ReceptorsPINKERTON ANTHONY B·Filed 2005·Application pending·0 cites
- 4034US2024245633A1ROR Gamma Agonists as Enhancers of Protective ImmunityUNIV FLORIDA·Filed 2016·Application pending·0 cites
- 4133US10758522B2Small molecule analogs of the nemo binding peptideSCRIPPS RESEARCH INST·Filed 2016·Granted Sep 1, 2020·0 cites·4 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →